IM1305 / Purple Biotech - LARVOL DELTA

CAPTN-3 unique design demonstrated by 2 novel platform compounds (ESMO-IO 2025) - "Here we present efficacy results for IM1240 (capped-CD3x5T4xNKG2A) in patient-derived refractory models, validating CAPTN-3 unique design structure, and introduce IM1305 (capped-CD3xTROP2xNKG2A).Methods Binding specificity of aCD3, aNKG2A and aTROP2 arms of IM1305 was measured by Octet (Kd), ELISA and FACS assays...A new TROP2-targeting compound demonstrated in-vitro and in-vivo activity with sustained tumor regression. CAPTN-3 candidate development is ongoing towards FIH studies.Legal entity responsible for the study Purple Biotech Ltd."

Head and Neck Cancer • Oncology • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • HLA-E • IL15 • KLRC1 • KLRD1 • TACSTD2